Associated Papers
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Ondrisova L et al.
Frontiers in Oncology, 2020
33154951 (PubMed )
Supplement: DataSheet_1.pdf
Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents.
Sedlarikova L et al.
Frontiers in Oncology, 2020
Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.
Albitar A et al.
Oncotarget, 2017
Select a paper to view details